Pediatric Rheumatology and Immunology, University Hospital Muenster, Domagkstr. 3, 48149, Muenster, Germany.
Research Group Ambient Intelligence, Saxion University of Applied Sciences, Enschede, The Netherlands.
Sci Rep. 2021 Mar 23;11(1):6690. doi: 10.1038/s41598-021-86251-w.
Crohn's disease (CD) and ulcerative colitis (UC) have a chronic-remittent course. Optimal management of inflammatory bowel diseases (IBD) relies on early intervention, treat-to-target strategies and a tight disease control. However, it is challenging to assess the risk of relapses in individual patients. We investigated blood-based biomarkers for the confirmation of disease remission in patients with IBD. We retrospectively analyzed samples of 40 IBD patients (30 UC, 10 CD) enrolled in a tight-control follow-up study. Half of the patients had a flare during follow up. Serum was analyzed for S100A12 as well as S100A8/A9 and for 50 further biomarkers in a bead-based multiplex assay. The concentrations of 9 cytokines/chemokines and S100A8/A9 significantly differed in IBD patients with unstable remission (before flares) when compared to IBD patients with stable remission. Although the number of patients was small, ROC curve analyses revealed a number of biomarkers (IL-1β, IL-1RA, IL-8, IL13, IL-15, IL-21, IL-25, IFN-β, CXCL9, CXCL10, CXCL11, Galectin-1, G-CSF and S100A8/A9) that were elevated in patients with later occurring relapses. While earlier studies on peripheral biomarkers in IBD are limited to only few analytes, our study using a broad screening approach identified serum biomarkers with the potential to indicate unstable disease control in IBD, which may help to steer individual therapies to maintain remission.
克罗恩病（CD）和溃疡性结肠炎（UC）具有慢性缓解-发作的病程。炎症性肠病（IBD）的最佳治疗策略依赖于早期干预、针对目标的治疗以及严格的疾病控制。然而，评估个体患者复发的风险具有挑战性。我们研究了用于确认 IBD 患者疾病缓解的基于血液的生物标志物。我们回顾性分析了 40 名参与严格控制随访研究的 IBD 患者（30 名 UC，10 名 CD）的样本。一半的患者在随访期间出现了发作。在基于珠的多重分析中，对血清进行了 S100A12 以及 S100A8/A9 的分析，并且对 50 种进一步的生物标志物进行了分析。与稳定缓解的 IBD 患者相比，缓解不稳定（发作前）的 IBD 患者的 9 种细胞因子/趋化因子和 S100A8/A9 的浓度有显著差异。尽管患者数量较少，但 ROC 曲线分析显示了一些生物标志物（IL-1β、IL-1RA、IL-8、IL13、IL-15、IL-21、IL-25、IFN-β、CXCL9、CXCL10、CXCL11、半乳糖凝集素-1、G-CSF 和 S100A8/A9）在后来发生发作的患者中升高。虽然之前关于 IBD 外周生物标志物的研究仅限于少数分析物，但我们使用广泛筛选方法的研究确定了具有指示 IBD 不稳定疾病控制潜力的血清生物标志物，这可能有助于指导个体化治疗以维持缓解。
